Chronic Lymphocytic Leukemia Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
View More
Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated…
View More
Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).
View More
Dr. Mato highlights data from “Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)…
View More
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia…
View More
In this video, John Allan, MD, Weill Cornell Medicine, discusses long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia with 4 years of follow-up in patients with TP53…
View More
Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.
View More
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.
View More
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
View More
Stay in the know.
OncNet Newsletter